Back to search results

Telehealth vs. In-Person Addiction Treatment After Emergency Department Care for Opioid Use Disorder

This study is comparing two ways to help people with Opioid Use Disorder (OUD) get ongoing treatment after they receive buprenorphine in the emergency department. Researchers want to see if referring people to telehealth (online or phone) treatment works better than referring them to in-person clinics. They will look at how long people stay on buprenorphine, a medication that helps treat OUD, and their overall experience with care. You might be able to join if you are an adult who received buprenorphine in the emergency department for OUD and don't already have an outpatient clinic for your buprenorphine. The main goal is to see how well people continue buprenorphine treatment for six months. The current status of this study is unclear, and it plans to enroll 528 participants.

Study design
This study is comparing two different types of referrals for OUD treatment. It plans to enroll 528 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint, buprenorphine retention, is measured at 6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06961058

Telehealth vs In-Person Evaluation of Addiction Treatment After Visiting the Emergency Department

Recruiting
NAAges 18+InterventionalHealth services
University of California, Davis
~528 participants
Updated 2026-06-29 on ClinicalTrials.gov
What's tested:referral to telehealth treatmentreferral to in person treatment

At a glance

Recruiting sites
3 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
buprenorphine retention
Measured over 6 months

Conditions

Opioid Use Disorder

Explore related trials

Opioid Use Disorder

Where it's being run

3 sites across 1 states
California3

Study leadership

  • Aimee Moulin, MD MAS · PRINCIPAL_INVESTIGATOR · University of California, Davis
  • Stephen G Henry, MD MSc · PRINCIPAL_INVESTIGATOR · University of California, Davis

Who to contact

Meghan Weyrich, MPH
[email protected]
916-734-7391
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adult patients who present to the emergency department and receive buprenorphine (either administered or prescribed) to treat OUD
do not have an established outpatient clinic where they will get buprenorphine when they leave the emergency department

Exclusion

inability to give consent
patients living in institutions (e.g., nursing homes, prisons)
unable to complete questionnaires in either English or Spanish

What this trial measures

  • buprenorphine retention6 months

    cumulative days with an active buprenorphine prescription